secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001485003-23-000031
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio merger partner Carisma appoints Moderna CSO Lin Guey to SAB; merger on track for Q1 2023
--------------------------------------------------------------------------------

- Carisma Therapeutics appointed Lin Guey, PhD (Chief Scientific Officer of Moderna's External Research Ventures) to its Scientific Advisory Board.
- Dr. Guey oversees Moderna's partnership with Carisma to develop in vivo engineered CAR-M therapies for cancer.
- Merger between Sesen Bio and Carisma expected to close in Q1 2023, subject to stockholder approval and other conditions.
- Carisma expects additional preclinical proof-of-concept data for its CAR-M therapy in Q1 2023.
- Moderna will fully fund R&D for up to 12 oncology targets under its collaboration with Carisma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000031/0001485003-23-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000031/sesn-20230207.htm
  HTML page:      https://secwatch.observer/filing/0001485003-23-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer